Drug prices to be included in TV ads under new rule
The Department of Health and Human Services announced a new policy to improve transparency in the pharmaceutical industry.
Starting this summer, TV commercials for prescription drugs covered by Medicaid or Medicare must mention the list price if it exceeds $35 for the standard treatment course or monthly supply. The policy has no enforcement mechanism but depends on companies suing rivals that violate the standard. The HHS will also publish a list of drugs with non-compliant ads.
“Patients who are struggling with high drug costs are in that position because of the high list prices that drug companies set,” HHS Secretary Alex Azar said in a press release. “Making those prices more transparent is a significant step in President Trump’s efforts to reform our prescription drug markets and put patients in charge of their own healthcare.”
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
FTXH in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 08, 2026
FTXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 39 cases where FTXH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +0.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTXH advanced for three days, in 254 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Aroon Indicator entered an Uptrend today. In 243 of 280 cases where FTXH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FTXH as a result. In 65 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for FTXH turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 34 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
FTXH moved below its 50-day moving average on October 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 72%.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement